Elequin Capital’s BeOne Medicines Ltd ONC Stock Holding History

Elequin Capital’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12	Closed	-$3.56K	–	929
2026 Q1	$3.56K	Buy	+12	New	+$3.88K	﹤0.01%	420

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Elequin Capital's ONC Position: Q2 2026 in Review

Elequin Capital sold out of BeOne Medicines Ltd (ONC) in Q2 2026, closing a stake of 12 shares — an estimated $3.56K sold.

Elequin Capital first reported a position in ONC in Q1 2026 and held it in 1 quarter. The position peaked at $3.56K in Q1 2026. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Elequin Capital reported no remaining BeOne Medicines Ltd position as of Q2 2026 after selling out during the quarter.
Elequin Capital sold 12 BeOne Medicines Ltd shares in Q2 2026, an estimated $3.56K.
Elequin Capital first reported a position in BeOne Medicines Ltd in Q1 2026 and held it in 1 quarter.
Elequin Capital's BeOne Medicines Ltd position peaked at $3.56K in Q1 2026.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Elequin Capital's 13F filing for Q2 2026, filed 13 Aug 2026.